Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer

PURPOSE: The IDEAL-CRT phase 1/2 multicenter trial of isotoxically dose-escalated concurrent chemoradiation for stage II/III non-small cell lung cancer investigated two 30-fraction schedules of 5 and 6 weeks’ duration. We report toxicity, tumor response, progression-free survival (PFS), and overall...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Int J Radiat Oncol Biol Phys
Main Authors: Fenwick, John D., Landau, David B., Baker, Angela T., Bates, Andrew T., Eswar, Chinnamani, Garcia-Alonso, Angel, Harden, Susan V., Illsley, Marianne C., Laurence, Virginia, Malik, Zafar, Mayles, William Philip M., Miles, Elizabeth, Mohammed, Nazia, Spicer, James, Wells, Paula, Vivekanandan, Sindu, Mullin, Anne-Marie, Hughes, Laura, Farrelly, Laura, Ngai, Yenting, Counsell, Nicholas
פורמט: Artigo
שפה:Inglês
יצא לאור: Elsevier, Inc 2020
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049901/
https://ncbi.nlm.nih.gov/pubmed/31809876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijrobp.2019.11.397
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים